Preoperative Mac‐2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma

Abstract

AimPostoperative ascites is one of the most common complications after hepatic resection and is related to liver fibrosis. Mac‐2 binding protein glycosylation isomer (M2BPGi) is a reliable and non‐invasive marker for assessing liver fibrosis. This study aimed to evaluate whether preoperative M2BPGi level can predict postoperative refractory ascites in patients with curative hepatic resection for hepatocellular carcinoma.MethodsThe present study retrospectively evaluated 59 patients between January 2016 and June 2018. We assessed the relationship between preoperative M2BPGi levels, expressed as the cut‐off index, and postoperative ascites.ResultsThe median M2BPGi level was 1.36 (range 0.34–11.56). Postoperative ascites occurred in seven patients (11.9%). Among them, refractory ascites, defined as diuretic‐resistant ascites, occurred in four patients (6.8%). Uni‐ and multivariate analysis showed that preoperative M2BPGi level was the only independent risk factor of postoperative ascites (odds ratio 3.28, P = 0.033). The cut‐off values of M2BPGi for postoperative ascites and refractory ascites were 2.41 and 3.10, respectively. Remarkably, there were no patients with postoperative ascites and refractory ascites when the preoperative M2BPGi levels were less than each cut‐off value.ConclusionOur results suggest that M2BPGi level is a reliable and non‐invasive surrogate marker for predicting postoperative ascites before curative resection for hepatocellular carcinoma.

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

“…16 86]. M2BPGi is reportedly useful as a predictive marker for liver failure and complications after hepatectomy or transcatheter arterial chemoembolization [82,[87][88][89][90][91]. Thus, M2BPGi level reflects not only liver fibrosis but also liver function.…”

“…M2BPGi levels increase as the disease progresses. M2BPGi can be used to assess disease status, such as that of liver fibrosis [31-38, 52-58, 71-75], HCC risk [31, 32, 36, 48-51, 53, 58, 62-69, 79, 104], HCC recurrence risk [92][93][94], liver function [82,[87][88][89][90][91], and prognosis of chronic liver diseases [82][83][84][85][86], with progression of the disease. In one relevant metaanalysis, the sensitivities and specificities for predicting significant fibrosis ( ≥ F2), advanced fibrosis ( ≥ F3), and cirrhosis were 0.690, 0.764, and 0.818 and 0.778, 0.758, and 0.839, respectively [21].…”

Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients

“…One finding of this study was the association between WFA+-M2BP and GEV. Some studies have shown the association between WFA+-M2BP and liver failure, hepatocellular carcinoma development, and its prognosis [21][22][23]. However, studies on the prediction of GEV are rare.…”

Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein as a predictive marker of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients

“…In liver surgery, Ishii et al . reported that WFA + ‐M2BP is a reliable marker to predict postoperative ascites after hepatectomy for HCC. The assay of WFA + ‐M2BP is easy, and does not require a long time to obtain the result. Yamasaki et al .…”